The organophosphorus pesticide chlorpyrifos (CPF) remains in use throughout the world despite its recent curtailment in the United States \[[@b49-ehp0113-001027], [@b50-ehp0113-001027]\]. The major concern for CPF is its propensity to elicit developmental neurotoxicity at exposure levels below the threshold for systemic toxicity, such that damaging exposures of pregnant women and children may go undetected because of the lack of symptoms ([@b21-ehp0113-001027]; [@b22-ehp0113-001027]; [@b26-ehp0113-001027]; [@b29-ehp0113-001027]; [@b30-ehp0113-001027]; [@b40-ehp0113-001027], [@b41-ehp0113-001027]; [@b52-ehp0113-001027]). CPF was originally thought to exert adverse effects on brain development through the same mechanism by which it elicits systemic toxicity, namely, inhibition of cholinesterase through its active metabolite, CPF oxon, but it is now evident that other, noncholinergic mechanisms participate in its developmental neurotoxicity ([@b6-ehp0113-001027]; [@b10-ehp0113-001027], [@b11-ehp0113-001027]; [@b16-ehp0113-001027]; [@b28-ehp0113-001027]; [@b30-ehp0113-001027]; [@b40-ehp0113-001027], [@b41-ehp0113-001027]). Even at exposures below the threshold for cholinesterase inhibition, CPF itself disrupts the patterns of neural cell replication and differentiation, axonogenesis and synaptogenesis, and the functional development of neurotransmitter and neurotrophin systems, culminating in aberrant behavioral performance ([@b6-ehp0113-001027]; [@b9-ehp0113-001027]; [@b16-ehp0113-001027]; [@b30-ehp0113-001027]; [@b34-ehp0113-001027], [@b36-ehp0113-001027]; [@b58-ehp0113-001027]). Consequently, CPF-induced damage extends beyond cholinergic pathways to include other neurotransmitter systems, notably the monoamines, norepinephrine, dopamine (DA), and serotonin (5HT), and recent studies show that 5HT systems are especially sensitive ([@b3-ehp0113-001027], [@b4-ehp0113-001027], [@b1-ehp0113-001027], [@b2-ehp0113-001027]; [@b37-ehp0113-001027]; [@b39-ehp0113-001027]).

In recent work we found that, during a critical developmental window centered around the immediate perinatal period, CPF elicits immediate and persistent effects on expression of 5HT receptors and the 5HT transporter, biomarkers for 5HT synaptic development and integrity ([@b3-ehp0113-001027], [@b4-ehp0113-001027], [@b1-ehp0113-001027]; [@b37-ehp0113-001027]). Additionally, we found that the same exposures elicited lasting changes in 5HT-related behaviors, resembling animal models of depression ([@b1-ehp0113-001027]). Notably, these studies were conducted spanning CPF exposures below the threshold for observable toxicity and, more important, could be detected at doses devoid of cholinesterase inhibition in the developing brain ([@b34-ehp0113-001027]). In the present study, we assessed 5HT levels and turnover, a measure of synaptic activity, in adulthood after prenatal or neonatal CPF exposure in order to provide a mechanistic link between effects on static biomarkers of 5HT synaptic development and altered behavior. Measurements were conducted using the metabolite ratio method ([@b44-ehp0113-001027]; [@b55-ehp0113-001027]), assessing the relative amounts of 5HT and its metabolite 5-hydroxyindole-acetic acid (5HIAA), with turnover calculated as the 5HIAA:5HT ratio. We examined brain regions with prominent 5HT innervation that are known to be targets for CPF ([@b3-ehp0113-001027], [@b4-ehp0113-001027], [@b2-ehp0113-001027]; [@b37-ehp0113-001027]). CPF exposure was carried out during the immediate perinatal period, the phase in which the receptor and transporter biomarkers indicate high susceptibility, or at a later postnatal development period in which these effects wane: exposure on gestational days (GD) 17--20 and postnatal days (PN) 1--4 and PN11--14 ([@b3-ehp0113-001027], [@b4-ehp0113-001027], [@b2-ehp0113-001027]; [@b37-ehp0113-001027]). Finally, effects on 5HT systems were contrasted to those on DA levels and turnover, again using the metabolite ratio method ([@b44-ehp0113-001027]; [@b55-ehp0113-001027]), assessing dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), calculating the ratio as \[DOPAC + HVA\]:DA.

Materials and Methods
=====================

Animal treatments.
------------------

All experiments using live animals were carried out in accordance with the Declaration of Helsinki ([@b54-ehp0113-001027]) and with the *Guide for the Care and Use of Laboratory Animals* as adopted and promulgated by the National Institutes of Health ([@b18-ehp0113-001027]). Timed-pregnant Sprague-Dawley rats (Zivic Laboratories, Pittsburgh, PA, USA) were housed in breeding cages, with a 12-hr light/dark cycle and with free access to food and water. CPF (Chem Service, West Chester, PA, USA) was dissolved in dimethyl sulfoxide to provide consistent absorption ([@b53-ehp0113-001027]) and was injected subcutaneously in a volume of 1 mL/kg body weight; control animals received equivalent dimethyl sulfoxide vehicle injections.

For exposure on GD17--20, dams were injected daily with CPF at 1 and 5 mg/kg body weight, doses that span the threshold for inhibition of fetal brain cholinesterase activity, fetal growth impairment, and reduced maternal weight gain, all of which become evident at ≥5 mg/kg ([@b15-ehp0113-001027]; [@b34-ehp0113-001027]). On the day of birth, all pups were randomized within their respective treatment groups and redistributed to the dams with a litter size of 10 to maintain a standard nutritional status. Randomization was repeated at intervals of 3 days, and in addition, within each treatment group, dams were rotated among litters to distribute any maternal caretaking differences randomly. Animals were weaned on PN21. On PN60, one male and one female were selected from each litter and were decapitated. The cerebellum, including flocculi, was removed, and the forebrain was separated from the midbrain and brainstem by a cut made rostral to the thalamus. The fore-brain was then further dissected into the regions containing major 5HT projections (cerebral cortex, hippocampus, striatum), and the midbrain and brainstem, which contain the preponderance of 5HT cell bodies, were separated from each other. The cerebellum, which is sparse in 5HT neurons or projections, was not evaluated. Tissues were frozen with liquid nitrogen and stored at −45°C.

For studies of CPF effects in the first few days after birth, animals were given a subcutaneous injection of 1 mg/kg daily on PN1--4; for studies in older animals, which tolerate higher doses ([@b7-ehp0113-001027]; [@b31-ehp0113-001027]; [@b32-ehp0113-001027]; [@b53-ehp0113-001027]), daily treatment with 5 mg/kg was given on PN11--14. The same randomization procedure was followed as described for prenatal CPF treatment. Neither regimen evoked weight loss or mortality ([@b7-ehp0113-001027]; [@b13-ehp0113-001027]; [@b19-ehp0113-001027]; [@b47-ehp0113-001027]). Samples were obtained on PN60 as described above.

Assays.
-------

Tissues were thawed and homogenized in ice-cold 0.1 M perchloric acid and sedimented for 20 min at 18,000 × *g*. The supernatant solution was collected, and aliquots were used for analysis of 5HT, 5HIAA, DA, HVA, and DOPAC by HPLC with electrochemical detection ([@b44-ehp0113-001027]; [@b55-ehp0113-001027]). Concurrently run standards, containing each of the neurotransmitters and metabolites (Sigma Chemical Co., St. Louis, MO, USA), were used to calculate the regional content of each neurochemical. DOPAC and HVA levels in the hippocampus were too low for accurate measurement. Transmitter levels were calculated as nanograms per region, and, because there were no treatment-related differences in brain region weights, the same effects were obtained with calculation as nanograms per gram of tissue or per milligram of protein (data not shown). Similarly, because 5HT and DA turnover were calculated as ratios of metabolites to transmitter, the values are independent of whether region, tissue weight, or protein concentration is used as the denominator term.

Data analysis.
--------------

Each treatment group comprised six males and six females. We compiled data as means ± SEs, and treatment-related differences were assessed by analysis of variance (ANOVA), with data log-transformed because of heterogeneous variance, incorporating factors of treatment (control, CPF), brain region, and sex. Where the initial test identified interactions of CPF treatment with region, we subdivided the effects into the individual brain regions and conducted lower-order tests to examine treatment and sex differences. Similarly, where ANOVA identified interactions of CPF with sex, we subdivided data to examine males and females separately. After subdivisions, we used Fisher's protected least significant difference to evaluate differences between individual groups. However, where CPF treatment did not interact with other variables, we assessed only the main treatment effect. Significance was assumed at the level of *p* \< 0.05 for main effects; however, for interactions at *p* \< 0.1, we examined lower-order main effects after subdivision of the interactive variables ([@b46-ehp0113-001027]).

To facilitate comparison of treatment effects across regions with widely differing transmitter levels or turnovers, some results are presented as the percentage change from control values. However, statistical evaluations were always conducted on the original data. Similarly, for convenience, control values for the three different treatment regimens were combined for presentation, but comparisons of CPF effects were conducted only with the appropriately matched control cohort. For reference, control values appear in [Table 1](#t1-ehp0113-001027){ref-type="table"}.

Results
=======

In brain regions of control rats, levels of 5HT, DA, and their metabolites showed few sex differences ([Table 1](#t1-ehp0113-001027){ref-type="table"}). 5HIAA was slightly higher in the striatum and midbrain of females, whereas DA levels were lower in midbrain and brainstem. None of the prenatal or postnatal treatment regimens evoked significant deficits in brain region weights (data not shown).

CPF exposure on GD17--20.
-------------------------

Across all brain regions, late gestational exposure to CPF elicited a significant net overall reduction (main treatment effect) in 5HT levels ([Figure 1A](#f1-ehp0113-001027){ref-type="fig"}). However, the effect was seen only at the higher dose (5 mg/kg), which elicits maternal weight deficits and significant fetal brain cholinesterase inhibition ([@b15-ehp0113-001027]; [@b34-ehp0113-001027]). Superimposed on the main treatment effect, there were regional differences: most regions showed a decrease in content, but values increased in the striatum. The pattern of effects on 5HT turnover was unrelated to the effects on 5HT content, with a main treatment effect representing a net increase ([Figure 1B](#f1-ehp0113-001027){ref-type="fig"}). In this case, however, effects were statistically significant at both 1 and 5 mg/kg, thus indicating increased 5HT turnover even at CPF exposures below the threshold for maternal toxicity or fetal brain cholinesterase inhibition. Again, some regions (hippocampus, brainstem) showed much larger changes than the others, particularly compared with the striatum.

The pattern of effects on DA levels and turnover differed substantially from those seen for 5HT. Although DA content was unaffected in most brain regions, there were massive deficits in the hippocampus with either the low or high dose of CPF ([Figure 2A](#f2-ehp0113-001027){ref-type="fig"}). DA turnover was affected only at the higher dose, with significant elevations in cerebral cortex, striatum, and midbrain ([Figure 2B](#f2-ehp0113-001027){ref-type="fig"}); DA turnover could not be assessed in the hippocampus because of the low levels of DA metabolites.

CPF exposure on PN1--4.
-----------------------

With early postnatal treatment, CPF elicited sex-selective alterations in 5HT content ([Figure 3A](#f3-ehp0113-001027){ref-type="fig"}). Males showed no significant change, whereas females showed a small but statistically significant net decrease. Again, the effects on 5HT turnover appeared to be unrelated to changes in 5HT content, displaying a net increase that was not sex selective and with the smallest magnitude of effect in the striatum ([Figure 3B](#f3-ehp0113-001027){ref-type="fig"}).

Effects on DA levels and turnover after CPF exposure on PN1--4 have appeared previously ([@b45-ehp0113-001027]), exhibiting decreases in cerebrocortical DA content and turnover, increases in both parameters in the striatum, and increased turnover in the midbrain.

CPF exposure on PN11--14.
-------------------------

Despite the use of a higher dose (5 mg/kg compared with 1 mg/kg on PN1--4) and the resultant greater degree of cholinesterase inhibition ([@b34-ehp0113-001027]; [@b47-ehp0113-001027]), CPF exposure during this later postnatal period had no significant effect on either 5HT content ([Figure 4A](#f4-ehp0113-001027){ref-type="fig"}) or turnover ([Figure 4B](#f4-ehp0113-001027){ref-type="fig"}). Earlier work for DA similarly found no alterations in either levels or turnover ([@b45-ehp0113-001027]).

Discussion
==========

In earlier work, we found that CPF exposure during a discrete developmental period in late gestation and early neonatal life elicits lasting up-regulation of the expression of 5HT synaptic proteins, including 5HT~1A~ and 5HT~2~ receptors and the presynaptic, high-affinity 5HT transporter ([@b4-ehp0113-001027]). The present results indicate that these changes in static 5HT biomarkers are associated with functional changes in 5HT levels, and, more important, in 5HT turnover, a dynamic index of synaptic activity. Moreover, the critical period for the alterations of transmitter turnover seen here corresponds precisely to that identified previously for the protein biomarkers, with closure of the window of vulnerability by the second postnatal week. In both cases, it is of critical importance that the lasting effects on 5HT function are elicited at CPF exposures below the threshold for systemic toxicity and even below that required for inhibition of fetal brain cholinesterase. The main findings here thus reinforce the idea that cholinesterase inhibition per se is an inadequate indicator of thresholds for CPF-induced developmental neurotoxicity.

The increase in 5HT turnover evoked by CPF exposure on either GD17--20 or PN1--4 is indicative of presynaptic hyperactivity, a particularly striking finding in light of the up-regulation of 5HT receptors evoked by the same treatments ([@b4-ehp0113-001027]). Ordinarily, increased 5HT concentrations in the synapse can be expected to evoke receptor down-regulation as a compensation for over-stimulation. As an initial impression, our finding of global presynaptic/postsynaptic up-regulation (receptors, transporter, turnover) might then suggest an overwhelming increase in 5HT function. However, evaluations of 5HT-linked behaviors and cell signaling both indicate quite the opposite, namely, deficiencies in 5HT function ([@b4-ehp0113-001027], [@b1-ehp0113-001027]). Accordingly, "miswiring" of 5HT circuits provides the most likely explanation for the effects of CPF on developing 5HT systems. If 5HT projections do not innervate the appropriate postsynaptic cells, then receptor up-regulation will occur because of the lack of neurotransmitter stimulation, and at the same, presynaptic neurons will be hyperactive as an attempt to compensate for the de facto lack of 5HT effect. With miswiring, these compensations cannot overcome the underlying architectural problem, leading to behavioral deficits resembling 5HT deficiencies as seen in animal models of depression ([@b1-ehp0113-001027]). Indeed, these types of circuitry defects also occur with prenatal xenobiotic insults that target cholinergic systems. Both phenobarbital and heroin disrupt the regional architecture of acetylcholine projections in the hippocampus, leading to parallel increases in cholinergic receptors, acetylcholine release, and expression of the presynaptic choline transporter, accompanied by behavioral and signaling defects that are not rectified by the combined presynaptic/ postsynaptic up-regulation ([@b48-ehp0113-001027]; [@b51-ehp0113-001027]; [@b56-ehp0113-001027]). If this interpretation is correct, deficits of 5HT function elicited by developmental exposure to CPF will also prove to be refractory to drugs that typically restore 5HT function, such as the 5HT reuptake inhibitors, resulting in drug-resistant depression. This possibility certainly deserves future examination.

Our findings also support the idea that CPF is frankly neurotoxic in the developing brain. We found decrements of 5HT levels in both males and females given the higher CPF dose on GD17--20 and also for the PN1--4 regimen in females. Nevertheless, the effects on 5HT turnover occurred at a dose below that required for loss of transmitter, suggesting that the miswiring effect is distinct from outright neurotoxicity. The effects on 5HT levels were also evident in the hippocampus, a region that we found in earlier work to be highly targeted for CPF-induced cellular damage and similar defects in cholinergic projections ([@b36-ehp0113-001027], [@b33-ehp0113-001027]; [@b42-ehp0113-001027]). In keeping with this, the present results showed prominent loss of hippocampal DA even at 1 mg/kg, a dose devoid of maternal or fetal toxicity or fetal cholinesterase inhibition ([@b15-ehp0113-001027]; [@b34-ehp0113-001027]). In previous work we found only minor effects on DA levels with CPF treatment on PN1--4, and no such effects with the PN11--14 regimen ([@b45-ehp0113-001027]), indicating early neonatal closing of the window of vulnerability for these particular neurotoxic events. Although hippocampal DA levels are lower than in the other regions, the loss of these projections is likely to play an important role in behavioral alterations. DA projections provide important regulatory inputs to hippocampal cholinergic synapses, with consequent effects on learning and memory ([@b57-ehp0113-001027]). Like the effects on 5HT turnover, we also found increased DA turnover after prenatal CPF exposure, with closure of the window of vulnerability in the second postnatal week ([@b45-ehp0113-001027]). The effects on 5HT thus represent one component of a larger spectrum of CPF-induced disruption of synaptic development and function that ultimately contribute to behavioral anomalies.

There are two additional features of the present results that are worth noting. First, with gestational CPF exposure, the loss of 5HT spared the striatum and similarly, whereas the hippocampus showed 40--50% loss of DA, there was no corresponding striatal decrement. Effectively, this regional difference de-emphasizes the importance of oxidative stress as a contributory mechanism for the neurotoxic actions of CPF because the striatum is typically more sensitive to such effects than other regions, largely due to its high content of DA, an oxidative neurotransmitter ([@b5-ehp0113-001027]; [@b12-ehp0113-001027]; [@b16-ehp0113-001027]; [@b20-ehp0113-001027]; [@b35-ehp0113-001027]). Indeed, we recently evaluated lipid peroxidation with each of the CPF regimens used here and found little or no evidence for oxidative damage with the GD17--20 or PN1--4 regimens, although lipid peroxidation was readily detected after exposure on PN11--14 ([@b43-ehp0113-001027]). Apparently, other, non-cholinesterase-related actions of CPF are more important contributors to neurobehavioral teratogenicity in the critical perinatal period in which 5HT systems are especially vulnerable ([@b6-ehp0113-001027]; [@b9-ehp0113-001027]; [@b16-ehp0113-001027]; [@b30-ehp0113-001027]; [@b34-ehp0113-001027], [@b36-ehp0113-001027]; [@b58-ehp0113-001027]), although oxidative stress may be relatively more important for later postnatal exposures. The second interesting characteristic is the relative lack of sex selectivity to the effects on 5HT turnover, whereas effects on behavior and 5HT receptor expression show distinct sex differences ([@b4-ehp0113-001027], [@b1-ehp0113-001027]). In fact, many of the functional consequences of CPF exposure represent the elimination of normal sex differences in synaptic function and behavior, partially masculinizing the patterns in females but feminizing males ([@b4-ehp0113-001027], [@b1-ehp0113-001027]). Accordingly, CPF may interfere with sexual differentiation of the brain, which peaks during the vulnerable perinatal period found here ([@b25-ehp0113-001027]; [@b27-ehp0113-001027]); as a consequence, even where CPF effects on males and females might be the same in regard to alterations of 5HT synaptic activity and/or miswiring of 5HT circuits, the outcome nevertheless can be expressed differently for males and females because of CPF's effects on sexual differentiation. Again, future studies should enable us to establish whether this explanation is correct.

In conclusion, the present results reinforce the concept that developmental CPF exposure, at doses below the threshold for maternal or fetal/neonatal toxicity, and below that required for inhibition of fetal brain cholinesterase, nevertheless causes lasting disruption of 5HT synaptic activity when exposure occurs in a critical developmental window centered around the immediate perinatal period. In combination with earlier studies of static synaptic protein biomarkers and 5HT-related behaviors ([@b4-ehp0113-001027], [@b1-ehp0113-001027]), the increase in 5HT turnover seen here suggests strongly that CPF acts through architectural miswiring of 5HT circuits, resulting in functional deficits despite global up-regulation of presynaptic and postsynaptic sensitivity. The developmental neuroteratogenicity of CPF thus encompasses neurotransmitter systems beyond those involving acetylcholine, and the effects seen here for 5HT and DA are likely to contribute to the emergence of behavioral alterations in adolescence and adulthood ([@b1-ehp0113-001027]; [@b8-ehp0113-001027]; [@b14-ehp0113-001027]; [@b17-ehp0113-001027]; [@b24-ehp0113-001027], [@b23-ehp0113-001027]; [@b38-ehp0113-001027]).
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![Effects of GD17--20 CPF exposure on (*A*) 5HT content and (*B*) turnover. ANOVA across treatment, region, and sex: (*A*), treatment, *p* \< 0.03; control versus 5 mg/kg, *p* \< 0.03; (*B*), treatment, *p* \< 0.007; control versus 1 mg/kg, *p* \< 0.05; control versus 5 mg/kg, *p* \< 0.002. Separate ANOVAs were not conducted for each region because of the absence of treatment × region interactions. Similarly, values are shown combined for males and females because of the lack of treatment × sex interactions.](ehp0113-001027f1){#f1-ehp0113-001027}

![Effects of GD17--20 CPF exposure on (*A*) DA content and (*B*) turnover. ANOVA across treatment, region, and sex: (*A*), treatment, *p* \< 0.04; treatment × region, *p* \< 0.02; (*B*), treatment, *p* \< 0.007; treatment × region, *p* \< 0.02.\
\*Individual treatments and regions are significantly different; values are shown combined for males and females because of the lack of treatment × sex interactions.](ehp0113-001027f2){#f2-ehp0113-001027}

![Effects of PN1--4 CPF (1 mg/kg) exposure on (*A*) 5HT content and (*B*) turnover. ANOVA across treatment, region, and sex: (*A*), treatment × sex, *p* \< 0.04; male, not significant; female, *p* \< 0.03; (*B*), treatment, *p* \< 0.0001 (separate ANOVAs for males and females were not evaluated because of the lack of a treatment × sex interaction). Separate ANOVAs were not conducted for each region because of the absence of treatment × region interactions.](ehp0113-001027f3){#f3-ehp0113-001027}

![Effects of PN11--14 CPF (5 mg/kg) exposure on (*A*) 5HT content and (*B*) turnover. ANOVA across treatment, region, and sex: not significant. Separate ANOVAs were not conducted for each region because of the absence of treatment × region interactions; similarly, values are shown combined for males and females because of the lack of treatment × sex interactions.](ehp0113-001027f4){#f4-ehp0113-001027}

###### 

Neurotransmitter and metabolite levels (ng/region) in control rat brain regions.

  Brain region      Sex      5HT        5HIAA                                                    DA                                                         DOPAC        HVA
  ----------------- -------- ---------- -------------------------------------------------------- ---------------------------------------------------------- ------------ --------
  Cerebral cortex   Male     267 ± 6    186 ± 5                                                  243 ± 9                                                    59 ± 2       42 ± 2
                    Female   255 ± 5    197 ± 5                                                  230 ± 12                                                   56 ± 2       42 ± 2
  Hippocampus       Male     113 ± 3    190 ± 5                                                  1.3 ± 0.2                                                  BD           BD
                    Female   114 ± 3    202 ± 5                                                  1.2 ± 0.2                                                  BD           BD
  Striatum          Male     165 ± 4    210 ± 5                                                  541 ± 13                                                   203 ± 7      55 ± 2
                    Female   173 ± 4    231 ± 5[\*](#tfn2-ehp0113-001027){ref-type="table-fn"}   470 ± 13[\*](#tfn2-ehp0113-001027){ref-type="table-fn"}    189 ± 6      50 ± 2
  Midbrain          Male     487 ± 15   299 ± 9                                                  31 ± 1                                                     16.1± 0.8    BD
                    Female   461 ± 13   324 ± 7[\*](#tfn2-ehp0113-001027){ref-type="table-fn"}   26 ± 1[\*](#tfn2-ehp0113-001027){ref-type="table-fn"}      14.1 ± 0.5   BD
  Brainstem         Male     189 ± 10   91 ± 6                                                   4.0 ± 0.2                                                  2.2 ± 0.2    BD
                    Female   188 ± 8    97 ± 7                                                   3.4 ± 0.1[\*](#tfn2-ehp0113-001027){ref-type="table-fn"}   2.2 ± 0.2    BD

BD, below detection limit.

\*Significant sex differences.
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